Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 2/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.33 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.32 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
| ▸ | RRM1 | P23921 | 1/20 | 0.30 |
| ▸ | SMYD2 | Q9NRG4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8175900 | 1.00 | TRPA1 (0.35) | TRPA1RIPK1GPR88KCNH3HTT | |
| SCHEMBL17006157 | 0.95 | TRPA1 (0.34) | TRPA1RIPK1KCNH3HTTCYP3A4 | |
| SCHEMBL17006154 | 0.95 | TRPA1 (0.34) | TRPA1RIPK1KCNH3HTTCYP3A4 | |
| SCHEMBL19331709 | 0.95 | TRPA1 (0.34) | TRPA1RIPK1KCNH3HTTCYP3A4 | |
| SCHEMBL14564989 | 0.91 | TRPA1 (0.40) | TRPA1RIPK1KCNH3HTTCYP3A4 | |
| SCHEMBL27032153 | 0.91 | TRPA1 (0.40) | TRPA1RIPK1KCNH3HTTCYP3A4 | |
| SCHEMBL8391322 | 0.91 | TRPA1 (0.40) | TRPA1RIPK1KCNH3HTTCYP3A4 | |
| SCHEMBL4192489 | 0.87 | TRPA1 (0.37) | TRPA1RIPK1GPR88KCNH3 | |
| SCHEMBL4192491 | 0.87 | TRPA1 (0.37) | TRPA1RIPK1GPR88KCNH3 | |
| SCHEMBL19331751 | 0.87 | ALDH1A1 (0.33) | CYP3A4ALDH1A1RRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023119098-A1 | PROTEIN KINASE C THETA INHIBITORS | Galderma Holding SA (CH) | 2023-06-29 | — | — | WO | disclosed |
| CN-112638868-B | Fatty acid derivatives labeled with positron radionuclides | 安斯泰来制药株式会社 | 2023-06-20 | — | — | CN | disclosed |
| US-7598289-B2 | Ketones and reduced ketones as therapeutic agents for the treatment of bone conditions | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2009-10-06 | — | — | US | disclosed |
| US-7572825-B2 | Ketones and reduced ketones as therapeutic agents for the treatment of bone conditions | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2009-08-11 | — | — | US | disclosed |
| US-20080312186-A1 | KETONES AND REDUCED KETONES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2008-12-18 | — | — | US | disclosed |
| EP-1638544-B1 | KETONES AND REDUCED KETONES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS | UNIV ABERDEEN (GB) | 2007-12-05 | — | — | EP | disclosed |
| US-20070027112-A1 | Ketones and reduced ketones as therapeutic agents for the treatment of bone conditions | UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN, THE (GB) | 2007-02-01 | — | — | US | disclosed |
| EP-1638544-A2 | KETONES AND REDUCED KETONES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS | The University Court of The University of Aberdeen (GB) | 2006-03-29 | — | — | EP | disclosed |
| WO-2004098582-A2 | KETONES AND REDUCED KETONES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2004-11-18 | — | — | WO | disclosed |
| WO-2000049019-A2 | NOVEL EPOTHILONE DERIVATIVES, METHOD FOR PRODUCING THEM AND THEIR PHARMACEUTICAL USE | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027112-A1 | Ketones and reduced ketones as therapeutic agents for the treatment of bone conditions | OXER1, ESRRA, NR5A1 | TRPA1 4719/4885RIPK1 116/4885GPR88 446/4885 |
| US-20080312186-A1 | KETONES AND REDUCED KETONES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS | AK1, IRAK1, CNKSR1 | TRPA1 4651/4885RIPK1 69/4885GPR88 1383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.